靶向心房颤动基质:JACC本周综述
本文为JACC综述,指出肺静脉隔离(PVI)是房颤消融的关键靶点,但单纯PVI常不能预防复发,多种附加消融策略亦未改善结局。作者强调应识别并干预心房和肺静脉内的促颤动基质,综述了针对心房心肌病(结构、电和/或自主神经病变)的新兴策略,包括危险因素管理、心外膜脂肪、纤维化、氧化应激和炎症小体等,并提倡早期积极抗房颤治疗。
要点
- 单纯PVI不足以预防多数患者房颤复发,需针对心房基质干预。
- 心房心肌病是房颤基质的基础,涉及结构、电和自主神经病变。
- 危险因素管理、心外膜脂肪、纤维化、氧化应激和炎症小体是潜在靶点。
核心结论
- 针对心房基质开发的治疗策略有望改善房颤消融和管理的结局。
研究设计与样本
- 综述类文章,检索范围未在摘要中报告。
主要发现
- PVI作为房颤消融关键靶点已被确立,但单纯PVI不能预防许多患者复发。
- 多种附加消融策略未能优于PVI结局,部分原因可能是未特异识别和干预促颤动基质。
- 针对心房心肌病的新兴方法包括危险因素管理、靶向心外膜脂肪、组织纤维化、氧化应激和炎症小体。
- 早期积极抗房颤治疗是管理策略之一。
临床怎么用
- 在房颤管理中应重视识别和干预心房基质,而非仅依赖PVI。
- 考虑将危险因素管理、心外膜脂肪、纤维化、氧化应激和炎症小体作为潜在治疗靶点。
- 提倡早期积极抗房颤治疗以对抗基质发展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The identification of the pulmonary veins as a trigger source for atrial fibrillation (AF) has established pulmonary vein isolation (PVI) as a key target for AF ablation. However, PVI alone does not prevent recurrent AF in many patients, and numerous additional ablation strategies have failed to improve on PVI outcomes. This therapeutic limitation may be due, in part, to a failure to identify and intervene specifically on the pro-fibrillatory substrate within the atria and pulmonary veins. In this review paper, we highlight several emerging approaches with clinical potential that target atrial cardiomyopathy-the underlying anatomic, electrical, and/or autonomic disease affecting the atrium-in various stages of practice and investigation. In particular, we consider the evolving roles of risk factor modification, targeting of epicardial adipose tissue, tissue fibrosis, oxidative stress, and the inflammasome, along with aggressive early anti-AF therapy in AF management. Attention to combatting substrate development promises to improve outcomes in AF.
引用
- McCauley MD, Iacobellis G, Li N, et al. Targeting the Substrate for Atrial Fibrillation: JACC Review Topic of the Week. J Am Coll Cardiol. 2024. PMID: 38749620. doi:10.1016/j.jacc.2024.02.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。